Eric Michael Przybyszewski, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatorenal Syndrome | 2 | 2024 | 76 | 1.060 |
Why?
|
| Liver Transplantation | 6 | 2024 | 2399 | 0.990 |
Why?
|
| Liver Cirrhosis | 7 | 2024 | 1950 | 0.840 |
Why?
|
| Waiting Lists | 2 | 2024 | 778 | 0.810 |
Why?
|
| Vasoconstrictor Agents | 1 | 2024 | 658 | 0.700 |
Why?
|
| Acute Kidney Injury | 4 | 2024 | 1943 | 0.670 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 1244 | 0.600 |
Why?
|
| Hemangiosarcoma | 1 | 2020 | 216 | 0.600 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2023 | 162 | 0.550 |
Why?
|
| Living Donors | 2 | 2018 | 651 | 0.530 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 4362 | 0.520 |
Why?
|
| End Stage Liver Disease | 4 | 2024 | 370 | 0.520 |
Why?
|
| Rectum | 1 | 2020 | 902 | 0.500 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 1031 | 0.490 |
Why?
|
| Hepatitis C | 1 | 2023 | 1594 | 0.430 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 1126 | 0.420 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2024 | 110 | 0.390 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2331 | 0.360 |
Why?
|
| Pennisetum | 2 | 2021 | 3 | 0.320 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 15965 | 0.310 |
Why?
|
| Graft Survival | 2 | 2018 | 3890 | 0.300 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4213 | 0.240 |
Why?
|
| Graft Rejection | 1 | 2018 | 4505 | 0.240 |
Why?
|
| Iron | 2 | 2021 | 1813 | 0.200 |
Why?
|
| Alcoholism | 2 | 2023 | 1993 | 0.200 |
Why?
|
| Ascites | 1 | 2023 | 339 | 0.190 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 179 | 0.170 |
Why?
|
| Food, Fortified | 2 | 2021 | 189 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2024 | 807 | 0.140 |
Why?
|
| Physical Exertion | 1 | 2020 | 669 | 0.140 |
Why?
|
| Histocompatibility | 1 | 2018 | 322 | 0.140 |
Why?
|
| Europe | 1 | 2024 | 3439 | 0.140 |
Why?
|
| Efficiency | 1 | 2020 | 477 | 0.140 |
Why?
|
| Hepacivirus | 1 | 2023 | 1342 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 563 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 617 | 0.130 |
Why?
|
| Fathers | 1 | 2018 | 377 | 0.120 |
Why?
|
| Natural Language Processing | 1 | 2024 | 1197 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 531 | 0.120 |
Why?
|
| Iron, Dietary | 1 | 2015 | 149 | 0.120 |
Why?
|
| Biopsy | 2 | 2024 | 6816 | 0.100 |
Why?
|
| Patient Selection | 1 | 2024 | 4266 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2023 | 3062 | 0.090 |
Why?
|
| Proteomics | 1 | 2023 | 3901 | 0.080 |
Why?
|
| Prognosis | 3 | 2024 | 30031 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2020 | 2901 | 0.080 |
Why?
|
| Humans | 18 | 2024 | 768369 | 0.070 |
Why?
|
| Mothers | 1 | 2018 | 2210 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2024 | 65408 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2016 | 2377 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2024 | 81835 | 0.060 |
Why?
|
| Liver | 1 | 2020 | 7575 | 0.060 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2020 | 373 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2024 | 283 | 0.050 |
Why?
|
| United States | 3 | 2024 | 73120 | 0.050 |
Why?
|
| Middle Aged | 8 | 2024 | 223406 | 0.050 |
Why?
|
| Male | 9 | 2024 | 364761 | 0.050 |
Why?
|
| Age Factors | 1 | 2018 | 18477 | 0.050 |
Why?
|
| India | 2 | 2020 | 2323 | 0.050 |
Why?
|
| Time Factors | 2 | 2024 | 40271 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 304 | 0.040 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 4052 | 0.040 |
Why?
|
| Nutritional Status | 2 | 2020 | 1623 | 0.040 |
Why?
|
| Necrosis | 1 | 2023 | 1622 | 0.040 |
Why?
|
| Tea | 1 | 2020 | 290 | 0.040 |
Why?
|
| Adolescent | 4 | 2021 | 89163 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1103 | 0.040 |
Why?
|
| Occupations | 1 | 2020 | 519 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2023 | 873 | 0.040 |
Why?
|
| Female | 9 | 2024 | 396926 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20763 | 0.030 |
Why?
|
| Ethanol | 1 | 2023 | 1334 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 36496 | 0.030 |
Why?
|
| Child | 3 | 2021 | 80856 | 0.030 |
Why?
|
| Risk Factors | 2 | 2024 | 74915 | 0.030 |
Why?
|
| Orosomucoid | 1 | 2015 | 45 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2525 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 42620 | 0.030 |
Why?
|
| Incidence | 2 | 2023 | 21552 | 0.030 |
Why?
|
| Donor Selection | 1 | 2016 | 240 | 0.030 |
Why?
|
| Receptors, Transferrin | 1 | 2015 | 300 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2022 | 1656 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 36840 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2016 | 588 | 0.030 |
Why?
|
| Ferritins | 1 | 2015 | 601 | 0.020 |
Why?
|
| Organ Size | 1 | 2016 | 2268 | 0.020 |
Why?
|
| Aged | 4 | 2024 | 171514 | 0.020 |
Why?
|
| Survival Rate | 1 | 2024 | 12875 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2021 | 54913 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3669 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2015 | 1532 | 0.020 |
Why?
|
| Adult | 4 | 2024 | 223528 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2023 | 15879 | 0.020 |
Why?
|
| Linear Models | 1 | 2015 | 5880 | 0.020 |
Why?
|
| Exercise | 1 | 2021 | 5940 | 0.010 |
Why?
|
| Hospitalization | 1 | 2024 | 10845 | 0.010 |
Why?
|
| Algorithms | 1 | 2024 | 14157 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3854 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 10358 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2015 | 12450 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2023 | 41782 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 26348 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39429 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 60038 | 0.010 |
Why?
|